Journal
CELL DEATH AND DIFFERENTIATION
Volume 17, Issue 3, Pages 482-487Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/cdd.2009.178
Keywords
RIPK1; CHX; TNF; cIAP1; NF-kappa B
Categories
Funding
- NHMRC [433013, 541901, 541902, 487348]
- Leukemia and Lymphoma Society [461221]
- Swiss National Science Foundation
Ask authors/readers for more resources
On TNF binding, receptor-interacting protein kinase 1 (RIPK1) is recruited to the cytoplasmic domain of TNFR1, at which it becomes ubiquitylated and serves as a platform for recruitment and activation of NEMO/IKK1/IKK2 and TAK1/TAB2. RIPK1 is commonly thought to be required for the activation of canonical NF-kappa B and for inhibition TNFR1-induced apoptosis. RIPK1 has, however, also been reported to be essential for TNFR1-induced apoptosis when cIAPs are depleted. To determine the role of RIPK1 in TNF/IAP antagonist-induced death, we compared wild type (WT) and RIPK1(-/-) mouse embryonic fibroblasts (MEFs) treated with these compounds. On being treated with TNF plus IAP antagonist, RIPK1(-/-) MEFs survived, unlike WT MEFs, demonstrating a killing activity of RIPK1. Surprisingly, however, on being treated with TNF alone, RIPK1(-/-) MEFs activated canonical NF-kappa B and did not die. Furthermore, several cell types from E18 RIPK1(-/-) embryos seem to activate NF-kappa B in response to TNF. These data indicate that models proposing that RIPK1 is essential for TNFR1 to activate canonical NF-kappa B are incorrect. Cell Death and Differentiation (2010) 17, 482-487; doi: 10.1038/cdd.2009.178; published online 20 November 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available